Standout Papers

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safe... 2010 2026 2015 2020 2.3k
  1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
    Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology
  2. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates (2014)
    Changyu Wang, Kent Thudium et al. Cancer Immunology Research

Immediate Impact

30 by Nobel laureates 21 from Science/Nature 126 standout
Sub-graph 1 of 17

Citing Papers

Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
2 intermediate papers

Works of Changyu Wang being referenced

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout
Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis
1998

Author Peers

Author Last Decade Papers Cites
Changyu Wang 1065 144 3100 1912 77 4.7k
Samir N. Khleif 1208 178 2898 1871 110 4.5k
Kaoru Abiko 941 675 2328 1794 97 3.9k
Paulette Mhawech‐Fauceglia 1895 636 1972 1596 125 4.9k
Heidi J. Gray 938 1345 2655 2057 92 4.7k
Shuang Qin 1295 74 2035 1348 71 3.7k
María E. Rodríguez-Ruiz 1306 37 3913 3470 89 6.1k
Maresa Altomonte 1576 36 2035 1688 94 4.3k
Gabriel Sica 1914 91 3884 2916 96 6.7k
Gal Markel 1513 174 2485 2946 126 5.6k
Jennifer H. Yearley 1070 46 3642 2595 56 5.5k

All Works

Loading papers...

Rankless by CCL
2026